7.510PLN+0.67%Mkt Cap: 121.38M PLNP/E: —Last update: 2026-06-01
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers dru…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap121.38M PLN
Enterprise Value138.96M PLN
Revenue (TTM)17.61M PLN
Gross Profit-17.41M PLN
Net Income (TTM)-62.61M PLN
Revenue/Share1.090 PLN
Last Price7.510 PLN
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees199
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLMBION00016
Valuation
P/E (Trailing)—
P/E (Forward)-3.36
PEG—
EV/EBITDA-3.65
EV/Revenue7.89
P/S6.85
P/B3.08
EPS (TTM)-3.53
EPS (Forward)-2.22
52W Range
6.70023% of range10.16
52W High10.16 PLN
52W Low6.700 PLN
Profitability
Gross Margin-110.52%
Oper. Margin-200.90%
EBITDA Margin-215.97%
Profit Margin-397.37%
ROE-128.23%
ROA-56.70%
Growth
Revenue Growth68.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.59M PLN
CapEx (TTM)892.00K PLN
FCF Margin-106.26%
FCF Yield-15.42%
Net Debt18.39M PLN
Net Debt/EBITDA-0.48
Balance Sheet
Debt/Equity0.26
Current Ratio0.31
Quick Ratio0.25
Book Value/Sh2.419 PLN
Cash/Share0.4270 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.16.16M
Float10.30M
Insiders31.62%
Institutions0.27%
Technical
SMA 508.178 (-8.2%)
SMA 2008.242 (-8.9%)
Beta0.41
S&P 52W Chg27.94%
Avg Vol (30d)34.83K
Avg Vol (10d)30.30K
Technical Indicators
RSI (14)43.8
MACD-0.1577
MACD Signal-0.1839
MACD Hist.+0.0262
BB Upper7.936 PLN
BB Middle7.527 PLN
BB Lower7.118 PLN
BB Width10.86%
ATR (14)0.3015 PLN
Vol Ratio (20d)0.39x